Earnings Growth of 0.9% Over 3 Years Hasn't Been Enough to Translate Into Positive Returns for Edwards Lifesciences (NYSE:EW) Shareholders
Earnings Growth of 0.9% Over 3 Years Hasn't Been Enough to Translate Into Positive Returns for Edwards Lifesciences (NYSE:EW) Shareholders
As an investor its worth striving to ensure your overall portfolio beats the market average. But the risk of stock picking is that you will likely buy under-performing companies. We regret to report that long term Edwards Lifesciences Corporation (NYSE:EW) shareholders have had that experience, with the share price dropping 45% in three years, versus a market return of about 11%. The more recent news is of little comfort, with the share price down 22% in a year. Even worse, it's down 34% in about a month, which isn't fun at all. This could be related to the recent financial results - you can catch up on the most recent data by reading our company report.
作爲投資者,值得努力確保您的整體投資組合能夠超過市場平均水平。但是,選股的風險在於您很可能會購買表現不佳的公司。我們很遺憾地報告,長揸愛德華生命科學公司(紐交所:EW)的股東們已經經歷了這種經歷,股價在三年內下跌了45%,而市場回報率約爲11%。最近的消息更糟糕,股價在一年內下跌了22%。更糟糕的是,它在大約一個月內下跌了34%,這一點都不好玩。這可能與最近的財務業績有關-您可以通過閱讀我們的公司報告來了解最新的數據。
Given the past week has been tough on shareholders, let's investigate the fundamentals and see what we can learn.
考慮到過去一週對股東來說是艱難的,讓我們調查一下基本面並看看我們能學到什麼。
To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
爲了概述本傑明·格雷厄姆(Benjamin Graham)的話:短期內,市場是一臺投票機,但長期來看,它是一臺衡重機。思考一家公司的市場感知如何轉變的一種不完美但簡單的方法是將每股收益(EPS)變化與股價變動進行比較。
During the unfortunate three years of share price decline, Edwards Lifesciences actually saw its earnings per share (EPS) improve by 2.9% per year. Given the share price reaction, one might suspect that EPS is not a good guide to the business performance during the period (perhaps due to a one-off loss or gain). Alternatively, growth expectations may have been unreasonable in the past.
在不幸的三年股價下跌期間,愛德華生命科學實際上看到其每股收益(EPS)每年提高2.9%。考慮到股價的反應,人們可能會懷疑EPS並不是該時期業績表現的良好指標(可能由於一次性損失或收益),或者過去的增長預期可能是不合理的。
After considering the numbers, we'd posit that the the market had higher expectations of EPS growth, three years back. But it's possible a look at other metrics will be enlightening.
經過綜合數值分析後,我們斷言市場在三年前對EPS的增長預期較高。但通過查看其他指標,可能能夠找到收益。
We note that, in three years, revenue has actually grown at a 6.2% annual rate, so that doesn't seem to be a reason to sell shares. This analysis is just perfunctory, but it might be worth researching Edwards Lifesciences more closely, as sometimes stocks fall unfairly. This could present an opportunity.
我們注意到,在三年內,營業收入實際上已以6.2%的年均增長率增長,因此似乎沒有賣出股票的理由。儘管這種分析只是敷衍了事,但深入研究愛德華生命科學可能是值得的,因爲有時股票會不公正地下跌,這可能會帶來機會。
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
你可以在下面的圖片中看到收入和營業收入隨時間的變化情況(單擊圖表可查看精確值)。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240809/0-7ace2fbcb9253880384fbecb1a0b6584-0-aae53da29e87197451386d8b38c908db.png/big)
Edwards Lifesciences is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. Given we have quite a good number of analyst forecasts, it might be well worth checking out this free chart depicting consensus estimates.
愛德華生命科學是一家知名股票,有許多分析師進行了覆蓋,這表明未來增長有一定的可見度。鑑於我們擁有相當數量的分析師預測,檢查描繪一致預期的免費圖表可能非常值得。
A Different Perspective
不同的觀點
Investors in Edwards Lifesciences had a tough year, with a total loss of 22%, against a market gain of about 16%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 3% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.
愛德華生命科學的投資者經歷了困難的一年,總虧損達22%,而市場獲得了約16%的收益。即使是好股票的股價有時也會下跌,但我們希望在產業基本指標改善之前不太感興趣。不幸的是,去年的表現結束了糟糕的路程,股東在五年內面臨年均3%的總虧損。總的來說,長期股價疲軟可能是一個不好的跡象,儘管持反對意見的投資者可能希望研究股票,希望實現扭轉局面。大多數投資者會花時間檢查內部交易的數據。您可以點擊此處查看內部人員是否一直在買賣。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.
當然,您可能在其他地方找到一家出色的企業進行投資。因此,請查看我們預計將實現盈利增長的公司的免費列表。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。